XNK receives certificate of GMP compliance of a manufacturer from the Medical Products Agency

XNK Therapeutics today announced that it has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies.

“We are very happy to receive this license. It is an important milestone for XNK, and we are now well positioned for significant value creation with three to four potential phase I/II readouts in our pipeline over the coming three years. The in-house GMP facility provides us with valuable capacity, flexibility and control over our clinical manufacturing which brings competitive advantages going forward. In addition, the close collaboration and proximity between manufacturing and research & innovation ensures efficient process development and organizational learning,” said Johan Liwing, CEO, XNK Therapeutics.

The building phase of the company’s new GMP clean room facility was completed in September 2022. The GMP facility comprises approximately 350 square meters and is located at XNK in the Novum Research Park, co-located with the Karolinska Institutet and the Karolinska University Hospital in Huddinge, Sweden.

“I am proud of the team which has worked hard over the past 18 months to build and validate our new GMP facility and a regulatory compliant Pharmaceutical Quality System. This will enable us of aseptic production of ATMPs for future clinical trials. This is an important step in the company’s ambitious growth plan to enable further larger clinical trials with our natural killer cell-based therapies,” said Linda Brink, Head of QA at XNK Therapeutics.

Academic Alliance to Shape the Future of Game Development in Flemingsberg

The game initiative Press Start Game Hub in Flemingsberg has now taken a major step forward in developing a sustainable game development ecosystem by launching its first academic collaboration group: Press Start Academic Group. The first meeting was held in June 2025 and brought together researchers and key figures from some of Sweden’s most prominent game development programs.

The Life Science business of Merck KGaA, Darmstadt, Germany Becomes a Trusted Partner of the Flemingsberg Science Foundation

The Life Science business of Merck KGaA, Darmstadt, Germany, and Flemingsberg Science Foundation collaborate to promote Life Science sector in Flemingsberg. This strategic partnership aims to strengthen development of ATMP (Advanced Therapy Medicinal Products).

Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future

In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.